Liana Alves de Oliveira

Dr. Liana Alves de Oliveira

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2016 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
GCGabriel A. Cipolla
Gabriel A. Cipolla
JPJong Kook Park
Jong Kook Park
LOLiana A. de Oliveira
Liana A. de Oliveira
SLSara Cristina Lobo-Alves
Sara Cristina Lobo-Alves
RARodrigo C. de Almeida
Rodrigo C. de Almeida
MPMaria-Luiza Petzl-Erler
Maria-Luiza Petzl-Erler


11 September 2008 in Genes & Immunity
Verified
Journal Article
Closed access
LOL A Oliveira
L A Oliveira
FRF Ribas
F Ribas
MBM G Bicalho
M G Bicalho
LTL T Tsuneto
L T Tsuneto
MPMaria-Luiza Petzl-Erler
Maria-Luiza Petzl-Erler

1 February 2021 in Nutrition Research
Verified
Journal Article
Closed access
JSJessica S M da Silva
Jessica S M da Silva
SBSimone Biesek
Simone Biesek
AVAudrin S Vojciechowski
Audrin S Vojciechowski
VBVictoria Z C Borba
Victoria Z C Borba
EREstela I Rabito
Estela I Rabito
LOLiana A Oliveira
Liana A Oliveira

1 January 2016 in Clinical Laboratory
Verified
Journal Article
Closed access
LOLiana Oliveira
Liana Oliveira
AMAlfredo Marquart-Filho
Alfredo Marquart-Filho
GTGerson Trevilato
Gerson Trevilato
RTRodolfo Timoteo
Rodolfo Timoteo
MMMaira Mukai
Maira Mukai
MPMaria-Luiza Petzl-Erler
Maria-Luiza Petzl-Erler
Pemphigus is a group of autoimmune blistering diseases of which the major forms are pemphigus foliaceus (PF) and vulgaris (PV). In Brazil, PF occurs in an endemic form also known as fogo selvagem. The main autoantibody in PF is against desmoglein 1 (DSG1), while in PV the main antibody is anti-desmoglein 3 (DSG3), but often anti-DSG1 is also present. The aim of the present study was to analyze the levels of anti-DSG1 and antiDSG3 autoantibodies in Brazilian PF and PV patients, considering different stages of the disease for PF patients and comparing these levels to those of healthy individuals living in and outside the endemic regions. Levels of anti-DSG1 and anti-DSG3 were measured in the sera of Brazilian PF (n = 68) and PV (n = 20) patients as well as in clinically healthy (control) individuals (n = 48) by Enzyme Linked Immunosorbent Assay (ELISA). Comparisons were made using Kruskal-Wallis and Mann-Whitney tests. As expected, anti-DSG1 was more prevalent among PF patients (84% against 43% in PV), while antiDSG3 was more prevalent in PV patients (50% against 4% in PF). Levels of anti-DSG1 in PF patients in remission differed from those in patients undergoing active disease (p = 0.003), and patients in long-term remission (more than two years without presenting new lesions) were similar to control individuals living in the endemic region and surrounding area (p = 0.09). Moreover, patients with a more severe form of the disease had higher levels of anti-DSG1 (at least 134 U/mL, mean of 233 U/mL) than patients with a less severe form (fewer lesions) (mean of 193 U/mL, including two negative individuals). Despite the importance of these antibodies for diagnosis and management purposes, their presence in a healthy individual and in patients under remission indicates that caution should be taken when using anti-DSG for diagnosis, especially in endemic areas.

8 February 2024 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
SLSara Cristina Lobo-Alves
Sara Cristina Lobo-Alves
LOLiana Alves de Oliveira
Liana Alves de Oliveira
Gabriela Canalli KretzschmarGabriela Canalli Kretzschmar
Gabriela Canalli Kretzschmar
AVAndressa Eloisa Valengo
Andressa Eloisa Valengo
RRRoberto Rosati
Roberto Rosati